The importance of managing diabetes correctly to prevent heart failure

References

• Kannel WB, Mcgee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA241(19), 2035–2038 (1979).
   PubMed Web of Science ®Google Scholar
• Thrainsdottir IS, Aspelund T, Gudnason V et al. Increasing glucose levels and BMI predict future heart failure experience from the Reykjavik Study. Eur. J. Heart Fail.9(10), 1051–1057 (2007).
   PubMedGoogle Scholar
• Ingelsson E, Sundstrom J, Arnlov J, Zethelius B, Lind L. Insulin resistance and risk of congestive heart failure. JAMA294(3), 334–341 (2005).
   PubMed Web of Science ®Google Scholar
• Matsushita K, Blecker S, Pazin-Filho A et al. The association of hemoglobin A1c with incident heart failure among people without diabetes: the atherosclerosis risk in communities study. Diabetes59(8), 2020–2026 (2010).
   PubMed Web of Science ®Google Scholar
• Kalogeropoulos A, Georgiopoulou V, Harris TB et al. Glycemic status and incident heart failure in elderly without history of diabetes mellitus: the health, aging, and body composition study. J. Card. Fail.15(7), 593–599 (2009).
   PubMedGoogle Scholar
• Macdonald MR, Petrie MC, Hawkins NM et al. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur. Heart J.29(10), 1224–1240 (2008).
   PubMedGoogle Scholar
• Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J. Am. Coll. Cardiol.54(19), 1747–1762 (2009).
   PubMed Web of Science ®Google Scholar
• Dobrin Js, Lebeche D. Diabetic cardiomyopathy: signaling defects and therapeutic approaches. Expert Rev. Cardiovasc. Ther.8(3), 373–391 (2010).
   PubMedGoogle Scholar
• Skyler JS, Bergenstal R, Bonow RO et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J. Am. Coll. Cardiol.53(3), 298–304 (2009).
   PubMed Web of Science ®Google Scholar
• Patel A, Macmahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with Type 2 diabetes. N. Engl. J. Med.358(24), 2560–2572 (2008).
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med.358(24), 2545–2559 (2008).
   PubMed Web of Science ®Google Scholar
• Horwich TB, Fonarow GC. Glucose, obesity, metabolic syndrome, and diabetes relevance to incidence of heart failure. J. Am. Coll. Cardiol.55(4), 283–293 (2010).
   PubMed Web of Science ®Google Scholar
• Nichols GA, Koro CE, Gullion CM, Ephross SA, Brown JB. The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab. Res. Rev.21(1), 51–57 (2005).
   PubMed Web of Science ®Google Scholar
• Giamouzis G, Triposkiadis F, Butler J. Metformin use in patients with diabetes mellitus and heart failure: friend or foe? J. Card. Fail.16(3), 207–210 (2010).
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial. Lancet366(9493), 1279–1289 (2005).
   PubMed Web of Science ®Google Scholar
• Aguilar D, Bozkurt B, Pritchett A, Petersen NJ, Deswal A. The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure. J. Am. Coll. Cardiol.50(1), 32–36 (2007).
   PubMedGoogle Scholar
• Schneider CA, Pfister R, Erdmann E. [Diabetes and heart failure]. Herz35(3), 140–146 (2010).
   PubMedGoogle Scholar
• Okerson T, Chilton RJ. The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc. Ther. DOI: 10.1111/j.1755–5922.2010.00256.x (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Turnbull F, Neal B, Algert C et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch. Intern. Med.165(12), 1410–1419 (2005).
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. BMJ317(7160), 703–713 (1998).
   PubMed Web of Science ®Google Scholar
• Kearney PM, Blackwell L, Collins R et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet371(9607), 117–125 (2008).
   PubMed Web of Science ®Google Scholar
• Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J. Card. Fail.3(4), 249–254 (1997).
   PubMedGoogle Scholar
• Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern. Med.142(4), 233–239 (2005).
   PubMed Web of Science ®Google Scholar
• Giamouzis G, Butler J. Relationship between heart failure and lipids: the paradigm continues to evolve. J. Card. Fail.13(4), 254–258 (2007).
   PubMedGoogle Scholar
• Adamopoulos C, Meyer P, Desai RV et al. Absence of obesity paradox in patients with chronic heart failure and diabetes mellitus: a propensity-matched study. Eur. J. Heart Fail.13(2), 200–206 (2010).
   PubMedGoogle Scholar